Drug and Therapeutics Bulletin 1999;37:6-8; doi:10.1136/dtb.1999.3716
Copyright © 1999 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

New fluoroquinolone antibiotics

Relevant BNF section: 5.1.12

In 1993, we reviewed three fluoroquinolone antibiotics (ciprofloxacin, norfloxacin and ofloxacin).1 Since then, four more fluoroquinolones have been awarded marketing authorisations. Here we review the clinical evidence and discuss the place of two of these drugs, {blacktriangledown}grepafloxacin (Raxar - GlaxoWellcome) and {blacktriangledown}levofloxacin (Tavanic - Hoechst Marion Roussel). Sparfloxacin and trovafloxacin are not considered, as they are not yet commercially available.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1999 BMJ Publishing Group Ltd.